Excluding patients who already had ESRD, the results showed that LN patients not on GLP-1Ras were twice as likely to progress to ESRD or dialysis dependence within five years compared to those using GLP-1Ras (OR 2.35, 95% CI 1.39, 3.976)
These drugs, often used for weight loss, have been associated with hundreds of adverse event reports, some requiring hospitalization
It is possible to achieve long-term results with proper maintenance and lifestyle support
If they cannot answer this, ask for the pharmacy contact information and call directly
Conclusion This cohort study demonstrates that semaglutide at lower doses compared to previously published is a feasible and cost-effective means of achieving weight loss for refractory obesity in post-operative bariatric patients
Complete medical history is required